Morristown, NJ, and Mumbai, India—A small new human trial suggests that Curcuwin Ultra+, a new ingredient from OmniActive Health Technologies, is more bioavailable than the standard 95% curcumin extract.
Specifically, the study—published in Advances in Therapy—found that 250mg Curcuwin Ultra+ was 144x more bioavailable than standard curcumin. A press release on the topic explains that this means that a single capsule containing 250mg of Curcuwin Ultra+ is equal to 30 capsules containing the standard extract. The study also found that Curcuwin Ultra+ absorbed 40% faster than standard curcumin.
The randomized, double-blind, three treatment, crossover oral bioavailability study included 24 healthy male and female volunteers between the ages of 18 and 55 years. Subjects received a single dose of Curcuwin Ultra+ in either a 250mg or 500mg dose or 1900mg of standard curcumin as per a randomization schedule. Blood samples were collected at 4h and 0h before dosing, and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, and 24h post dose.
The researchers concluded: “[Curcuwin Ultra+], which is designed for increased absorption and protection of curcuminoids from intestinal degradation, demonstrated superior bioavailability as compared to [standard curcumin] at considerably smaller doses. Additional clinical studies will help to demonstrate the impact of its increased bioavailability on efficacy.”
In a press release, Deshanie Rai, Ph.D., FACN, VP, Global Scientific and Regulatory Affairs at OmniActive, commented:“OmniActive continues to champion innovation and invest in science for the betterment of human nutrition. Having our data selected to be presented at the prestigious EB meeting and accepted for publication in the well-respected peer-reviewed journal Advances in Therapy speaks to the strength and relevance of this new science.”
Curcuwin Ultra+ will be commercially available midyear. Interested parties can reach out to firstname.lastname@example.org.